NCT06229912招募中2 期
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 3
- 主要终点
- Safety and adverse events (AEs)
研究概览
简要总结
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
详细描述
Primary Objectives
• To assess the efficacy of revumenib in leukemias associated with upregulation of HOX genes.
Secondary Objectives
- To assess rates of measurable residual disease (MRD) clearance, as assessed by multiparameter flow cytometry in participants who respond to treatment.
- To assess rates of cytogenetic remissions in participants with baseline cytogenetic abnormalities at diagnosis.
- To assess event-free survival (EFS), duration of response (DOR), and overall survival (OS) in participants with leukemia associated with upregulation of HOX following treatment with revumenib.
Exploratory Objectives
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 12 years with weight ≥ 40Kg.
- •ECOG performance status of ≤
- •Relapsed or refractory acute leukemia, of either myeloid, lymphoid or mixed lineages, with genetic alterations associated with upregulation of HOX, as specified below:
- •Alteration/Mutation - Cytogenetics KMT2A-PTD = Normal karyotype; NPM1-MLF1 = t(3;5)(q25;q34); NUP98r = 11p15 rearrangements; SET-NUP214 = t(9;9)(q34;q34); RUNX1-EVI1 = t(3;21)(q26;q22); MYST3-CREBBP = t(8;16)(p11;p13); CDX2-ETV6 = t(12;13)(p13;q12); CALM-AF10 = t(10;11)(p13;q14-21); MN1-ETV6 = t(12;22)(p13;q12); UBTF-TD = Normal karyotype
- •WBC must be below 25,000/ uL at time of enrollment. Participants may receive cytoreduction prior to enrollment.
- •Baseline ejection fraction must be > 40%.
- •Adequate hepatic function (direct bilirubin < 1.5x upper limit of normal (ULN) unless increase is due leukemic involvement, and AST and/or ALT < 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5x ULN will be considered eligible).
- •Adequate renal function with an estimated glomerular filtration rate ≥ 60 mL/min based on local institutional practice for age-appropriate determination.
- •Participants or parent/guardian is willing and able to provide informed consent.
- •In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 14 days for cytotoxic or non-cytotoxic (immunotherapy agent(s), or an interval of 5 half-lives of the prior therapy. Oral hydroxyurea and/or cytarabine (up to 2 g/m2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principal investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted.
- •Women of childbearing potential must agree to adequate methods of contraception during the study and at least 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and at least 3 months after the last treatment.
排除标准
- •Participants with any concurrent uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the participant at unacceptable risk of study treatment.
- •The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled CNS leukemia. (2) use of hydroxyurea for participants with rapidly proliferative disease or for control of counts during differentiation syndrome. (3) use of steroids for treatment of differentiation syndrome.
- •Participants with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.
- •Participants with concurrent active malignancy under treatment.
- •Known active hepatitis B (HBV) or hepatitis C (HCV) or human immunodeficiency virus (HIV) infections.
- •Female subjects who are pregnant or breast-feeding.
- •Participant has an active uncontrolled infection.
- •Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.
- •QTc >450 msec for males and QTc >470 msec for females using the Fridericia Formula using an average of the 3 Screening EKGs.
- •History of or any concurrent condition, therapy, or laboratory abnormality that in the Investigator's opinion might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
- •Clinically active central nervous system (CNS) leukemia.
- •Participants on immunosuppressive therapy post-HSCT at the time of screening (must be off all systemic immunosuppression therapy for at least 2 weeks and calcineurin inhibitors for at least 4 weeks). The use of topical steroids for cutaneous graft-versus-host disease (GVHD) or stable systemic steroid doses less than or equal to 20 mg of prednisone (or equivalent) daily are permitted.
- •Participants with Grade > 2 active acute GVHD, moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity.
研究组 & 干预措施
Arm 1
Experimental
Participants found to be eligible to take part in this study, will take revumenib 2 times a day (each dose about 12 hours apart), every day of each 28-day study cycle.
干预措施: Revumenib (Drug)
结局指标
主要结局
Safety and adverse events (AEs)
时间窗: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRecurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRefractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRefractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRefractory Mixed Phenotype Acute LeukemiaNCT05761171Children's Oncology Group78
已完成
2 期
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeAcute Myelogenous LeukemiaMyelodysplastic SyndromeNCT00360672M.D. Anderson Cancer Center27
已完成
2 期
Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsAcute Myeloid LeukemiaNCT00957385University Health Network, Toronto24
已完成
2 期
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell TransplantAcute Biphenotypic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic Cell Transplantation RecipientAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaNCT03267186Andrew Rezvani8
已完成
2 期
Nivolumab in AML in Remission at High Risk for RelapseAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionBlasts Under 10 Percent of Bone Marrow Nucleated CellsTherapy-Related Myeloid NeoplasmNCT02532231M.D. Anderson Cancer Center15